Deutsche lowers target on Tesaro

"We had expected the trial to hit on nausea — we were wrong," Deutsche Bank's Robyn Karnauskas says, referencing Phase 3 results for rolapitant, Tesaro's (TSRO) NK-1 receptor antagonist.

Karnauskas lowers the price target on the shares to $62 from $80, noting that Deutsche now sees 40% market share for the drug.

"Worst case, stock could be flat near term until launch gets closer when we think many will want to own," the analyst concludes.

TSRO +2.2% premarket.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs